A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Wave Life Sciences Ltd. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 9,703,351 shares of WVE stock, worth $138 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
9,703,351
Previous 5,357,719 81.11%
Holding current value
$138 Million
Previous $26.7 Million 197.61%
% of portfolio
0.15%
Previous 0.05%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.12 - $9.01 $22.2 Million - $39.2 Million
4,345,632 Added 81.11%
9,703,351 $79.6 Million
Q2 2024

Aug 14, 2024

BUY
$4.38 - $6.48 $684,725 - $1.01 Million
156,330 Added 3.01%
5,357,719 $26.7 Million
Q1 2024

May 15, 2024

SELL
$3.54 - $6.84 $2.78 Million - $5.38 Million
-786,341 Reduced 13.13%
5,201,389 $32.1 Million
Q4 2023

Feb 14, 2024

BUY
$4.16 - $6.87 $9.15 Million - $15.1 Million
2,200,000 Added 58.08%
5,987,730 $30.2 Million
Q3 2023

Nov 14, 2023

SELL
$3.56 - $5.75 $2.96 Million - $4.78 Million
-831,179 Reduced 18.0%
3,787,730 $21.8 Million
Q1 2023

May 15, 2023

SELL
$3.58 - $6.3 $3.25 Million - $5.72 Million
-907,975 Reduced 16.43%
4,618,909 $20 Million
Q4 2022

Feb 14, 2023

BUY
$3.18 - $7.0 $13.1 Million - $28.9 Million
4,125,495 Added 294.39%
5,526,884 $38.7 Million
Q3 2022

Nov 14, 2022

SELL
$2.37 - $4.28 $3.19 Million - $5.76 Million
-1,345,752 Reduced 48.99%
1,401,389 $5.06 Million
Q2 2022

Aug 15, 2022

BUY
$1.23 - $3.25 $2.83 Million - $7.47 Million
2,297,141 Added 510.48%
2,747,141 $8.93 Million
Q4 2021

Feb 14, 2022

BUY
$3.14 - $5.15 $157,000 - $257,500
50,000 Added 12.5%
450,000 $1.41 Million
Q3 2021

Nov 15, 2021

BUY
$4.89 - $7.12 $1.96 Million - $2.85 Million
400,000 New
400,000 $1.96 Million

Others Institutions Holding WVE

About Wave Life Sciences Ltd.


  • Ticker WVE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,820,096
  • Market Cap $1.24B
  • Description
  • Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...
More about WVE
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.